Peripheral T/natural killer-cell lymphoma involving the female genital tract

a clinicopathologic study of 5 cases.

S. Nakamura, M. Kato, K. Ichimura, Y. Yatabe, Y. Kagami, R. Suzuki, H. Taji, E. Kondo, S. Asakura, M. Kojima, S. Murakami, K. Yamao, T. Tsuzuki, G. K. Adachi, A. Miwa, T. Yoshidai

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Malignant lymphoma of the female genital tract (FGT) is rare. In this study, 5 peripheral T/natural killer (NK)-cell lymphomas (PTCLs) involving the FGT are reported. They include 2 from the uterus and 1 each from ovary, uterus and ovary, and vagina, and were detected between 1996 and 2000. One of the 2 ovarian tumors was bilateral. In all cases, the FGT was the initial site of clinical presentation of disease. Age at presentation ranged from 21 to 52 years (median, 36 years). One case was stage I disease, 2 were stage II, and 2 were stage IV. All 5 tumors were positive for CD3epsilon, and 3 harbored the Epstein-Barr virus, although the detailed immunophenotypic profiles varied. Three were diagnosed as nasal type T/NK-cell lymphoma, 1 as anaplastic large-cell lymphoma (anaplastic lymphoma kinase [ALK]-positive), and 1 as unspecified PTCL of cytotoxic phenotype, according to the forthcoming World Health Organization classification. Four of 5 patients received laparotomy and chemotherapy. Four patients (in stages II and IV) died of disease within 16 months of the initial diagnosis, whereas only 1 patient (in stage I) is alive without disease at 39 months of follow-up. Our experience in this series provided clinically relevant information on diagnosis, treatment, and outcome for extremely rare tumors of the FGT.

Original languageEnglish
Pages (from-to)108-114
Number of pages7
JournalInternational Journal of Hematology
Volume73
Issue number1
Publication statusPublished - Jan 2001
Externally publishedYes

Fingerprint

Natural Killer T-Cells
Lymphoma
Uterus
Ovary
Anaplastic Large-Cell Lymphoma
Neoplasms
Vagina
Human Herpesvirus 4
Nose
Laparotomy
Phenotype
Drug Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Nakamura, S., Kato, M., Ichimura, K., Yatabe, Y., Kagami, Y., Suzuki, R., ... Yoshidai, T. (2001). Peripheral T/natural killer-cell lymphoma involving the female genital tract: a clinicopathologic study of 5 cases. International Journal of Hematology, 73(1), 108-114.

Peripheral T/natural killer-cell lymphoma involving the female genital tract : a clinicopathologic study of 5 cases. / Nakamura, S.; Kato, M.; Ichimura, K.; Yatabe, Y.; Kagami, Y.; Suzuki, R.; Taji, H.; Kondo, E.; Asakura, S.; Kojima, M.; Murakami, S.; Yamao, K.; Tsuzuki, T.; Adachi, G. K.; Miwa, A.; Yoshidai, T.

In: International Journal of Hematology, Vol. 73, No. 1, 01.2001, p. 108-114.

Research output: Contribution to journalArticle

Nakamura, S, Kato, M, Ichimura, K, Yatabe, Y, Kagami, Y, Suzuki, R, Taji, H, Kondo, E, Asakura, S, Kojima, M, Murakami, S, Yamao, K, Tsuzuki, T, Adachi, GK, Miwa, A & Yoshidai, T 2001, 'Peripheral T/natural killer-cell lymphoma involving the female genital tract: a clinicopathologic study of 5 cases.', International Journal of Hematology, vol. 73, no. 1, pp. 108-114.
Nakamura, S. ; Kato, M. ; Ichimura, K. ; Yatabe, Y. ; Kagami, Y. ; Suzuki, R. ; Taji, H. ; Kondo, E. ; Asakura, S. ; Kojima, M. ; Murakami, S. ; Yamao, K. ; Tsuzuki, T. ; Adachi, G. K. ; Miwa, A. ; Yoshidai, T. / Peripheral T/natural killer-cell lymphoma involving the female genital tract : a clinicopathologic study of 5 cases. In: International Journal of Hematology. 2001 ; Vol. 73, No. 1. pp. 108-114.
@article{ab164f9eb91e4ce9b53222542203c8fb,
title = "Peripheral T/natural killer-cell lymphoma involving the female genital tract: a clinicopathologic study of 5 cases.",
abstract = "Malignant lymphoma of the female genital tract (FGT) is rare. In this study, 5 peripheral T/natural killer (NK)-cell lymphomas (PTCLs) involving the FGT are reported. They include 2 from the uterus and 1 each from ovary, uterus and ovary, and vagina, and were detected between 1996 and 2000. One of the 2 ovarian tumors was bilateral. In all cases, the FGT was the initial site of clinical presentation of disease. Age at presentation ranged from 21 to 52 years (median, 36 years). One case was stage I disease, 2 were stage II, and 2 were stage IV. All 5 tumors were positive for CD3epsilon, and 3 harbored the Epstein-Barr virus, although the detailed immunophenotypic profiles varied. Three were diagnosed as nasal type T/NK-cell lymphoma, 1 as anaplastic large-cell lymphoma (anaplastic lymphoma kinase [ALK]-positive), and 1 as unspecified PTCL of cytotoxic phenotype, according to the forthcoming World Health Organization classification. Four of 5 patients received laparotomy and chemotherapy. Four patients (in stages II and IV) died of disease within 16 months of the initial diagnosis, whereas only 1 patient (in stage I) is alive without disease at 39 months of follow-up. Our experience in this series provided clinically relevant information on diagnosis, treatment, and outcome for extremely rare tumors of the FGT.",
author = "S. Nakamura and M. Kato and K. Ichimura and Y. Yatabe and Y. Kagami and R. Suzuki and H. Taji and E. Kondo and S. Asakura and M. Kojima and S. Murakami and K. Yamao and T. Tsuzuki and Adachi, {G. K.} and A. Miwa and T. Yoshidai",
year = "2001",
month = "1",
language = "English",
volume = "73",
pages = "108--114",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - Peripheral T/natural killer-cell lymphoma involving the female genital tract

T2 - a clinicopathologic study of 5 cases.

AU - Nakamura, S.

AU - Kato, M.

AU - Ichimura, K.

AU - Yatabe, Y.

AU - Kagami, Y.

AU - Suzuki, R.

AU - Taji, H.

AU - Kondo, E.

AU - Asakura, S.

AU - Kojima, M.

AU - Murakami, S.

AU - Yamao, K.

AU - Tsuzuki, T.

AU - Adachi, G. K.

AU - Miwa, A.

AU - Yoshidai, T.

PY - 2001/1

Y1 - 2001/1

N2 - Malignant lymphoma of the female genital tract (FGT) is rare. In this study, 5 peripheral T/natural killer (NK)-cell lymphomas (PTCLs) involving the FGT are reported. They include 2 from the uterus and 1 each from ovary, uterus and ovary, and vagina, and were detected between 1996 and 2000. One of the 2 ovarian tumors was bilateral. In all cases, the FGT was the initial site of clinical presentation of disease. Age at presentation ranged from 21 to 52 years (median, 36 years). One case was stage I disease, 2 were stage II, and 2 were stage IV. All 5 tumors were positive for CD3epsilon, and 3 harbored the Epstein-Barr virus, although the detailed immunophenotypic profiles varied. Three were diagnosed as nasal type T/NK-cell lymphoma, 1 as anaplastic large-cell lymphoma (anaplastic lymphoma kinase [ALK]-positive), and 1 as unspecified PTCL of cytotoxic phenotype, according to the forthcoming World Health Organization classification. Four of 5 patients received laparotomy and chemotherapy. Four patients (in stages II and IV) died of disease within 16 months of the initial diagnosis, whereas only 1 patient (in stage I) is alive without disease at 39 months of follow-up. Our experience in this series provided clinically relevant information on diagnosis, treatment, and outcome for extremely rare tumors of the FGT.

AB - Malignant lymphoma of the female genital tract (FGT) is rare. In this study, 5 peripheral T/natural killer (NK)-cell lymphomas (PTCLs) involving the FGT are reported. They include 2 from the uterus and 1 each from ovary, uterus and ovary, and vagina, and were detected between 1996 and 2000. One of the 2 ovarian tumors was bilateral. In all cases, the FGT was the initial site of clinical presentation of disease. Age at presentation ranged from 21 to 52 years (median, 36 years). One case was stage I disease, 2 were stage II, and 2 were stage IV. All 5 tumors were positive for CD3epsilon, and 3 harbored the Epstein-Barr virus, although the detailed immunophenotypic profiles varied. Three were diagnosed as nasal type T/NK-cell lymphoma, 1 as anaplastic large-cell lymphoma (anaplastic lymphoma kinase [ALK]-positive), and 1 as unspecified PTCL of cytotoxic phenotype, according to the forthcoming World Health Organization classification. Four of 5 patients received laparotomy and chemotherapy. Four patients (in stages II and IV) died of disease within 16 months of the initial diagnosis, whereas only 1 patient (in stage I) is alive without disease at 39 months of follow-up. Our experience in this series provided clinically relevant information on diagnosis, treatment, and outcome for extremely rare tumors of the FGT.

UR - http://www.scopus.com/inward/record.url?scp=0035235269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035235269&partnerID=8YFLogxK

M3 - Article

VL - 73

SP - 108

EP - 114

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 1

ER -